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The human papillomavirus (HPV) E1^E4 protein is detected in the cytoplasm of differentiated keratinocytes, near the cornified cell envelope.
HPV does not induce lysis of the infected keratinocyte, and the normally durable cornified cell envelope that forms during keratinocyte
differentiation would seemingly inhibit viral egress. HPV infection induces abnormalities of the cornified cell envelope, but the exact mechanisms
involved are not well understood. We tested whether the HPV 11 E1^E4 protein, which co-localizes the cell envelope and co-purifies with cell
envelope fragments, could serve as an in vitro substrate for transglutaminases. We found evidence of E1^E4 cross-linking by endogenous
transglutaminases in an in situ assay using frozen sections of human foreskin, and in addition, E1^E4 protein was cross-linked by recombinant
transglutaminase 3 (but not transglutaminase 1) in an in vitro cross-linking assay. We also tested whether expression of E1^E4 in differentiated
keratinocytes would induce morphologic alterations of cornified cell envelopes. Differentiated keratinocytes expressing E1^E4 were disorganized
and pleomorphic compared to control cells, and cell envelopes purified from E1^E4-expressing cells were small, fragmented, and rough bordered
compared to the round, smooth bordered cell envelopes from control cells. We conclude from these in vitro experiments that the E1^E4 protein is
cross-linked by transglutaminase 3, and that E1^E4 expression in differentiated keratinocytes induces morphologic abnormalities of the cornified
cell envelope.
D 2005 Elsevier Inc. All rights reserved.Keywords: Human Papillomavirus; E1^E4; Cornified cell envelopeIntroduction
Human papillomaviruses (HPVs) infect epithelial tissues,
including those of the genitalia. HPV types 6 and 11 cause
condylomata acuminata, or genital warts (Brown et al., 1993;
Ferenczy, 1995; Gissmann et al., 1982). These proliferative
lesions often produce virions that are detected in differentiated
keratinocytes, cells that have developed a cornified cell
envelope (Ferenczy et al., 1981; Firzlaff et al., 1988; Morin
et al., 1981; Toki et al., 1986). The cornified cell envelope is a
dense matrix of proteins and lipids covalently cross-linked by
the enzymatic activity of keratinocyte transglutaminases (Eck-0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: darbrow@iupui.edu (D.R. Brown).ert et al., 1997; Kalinin et al., 2002; Reichert et al., 1993; Rice
and Green, 1977; Steinert and Marekov, 1999). The endpoint
of keratinocyte differentiation is a layer of flattened, durable,
enucleated cornified cell envelopes that provides the host with
barrier protection.
In contrast to many other virus infections, HPV does not
induce lysis of the target cell (Lehr and Brown, 2002). The
virus must be able to escape the infected keratinocyte for
transmission of infection, and the mechanisms for this process
are not well understood. The cornified cell envelope in its
normal, durable state would seemingly hinder virion release
from desquamated keratinocytes.
We have theorized that a defect in the cornified cell
envelope could facilitate release of virions. We showed that
natural HPV 11 infection induces cell envelope abnormalities,
and that desquamated, cornified cells are effective transmitters
of virus (Brown and Bryan, 2000; Bryan and Brown, 2001).6) 290 – 298
www.e
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localizes to the region of the cell envelope in immunohisto-
chemical assays, co-purifies with cell envelope fragments, and
is associated with the cell envelope structure in immunoelec-
tron microscopic studies (Bryan and Brown, 2000). In the
current study, we performed experiments to determine if
keratinocyte transglutaminases could cross-link the HPV 11
E1^E4 protein. We next performed experiments to determine if
expression of E1^E4 in differentiated human keratinocytes
induced alterations in the morphologic characteristics of the
cornified cell envelope.
Results
Expression of recombinant proteins
Recombinant viral and cellular proteins were expressed and
purified for these experiments. Hexa-histidine-tagged (his-
tagged) HPV 11 E1^E4 protein was purified from bacterial
using nickel columns, then analyzed in SDS-PAGE gels (Fig.
1, Panel A, Lane 1) and immunoblots (Fig. 1, Panel A, Lane 3).
Freshly purified, his-tagged E1^E4 appeared in the gel as a
single band of approximately 15 kDa, and as a doublet of
approximately 14 and 15 kDa in the immunoblots using an
antibody against the his-tag.
His-tagged loricrin was expressed in SF21 insect cells, then
purified using nickel columns and analyzed in SDS-PAGE gels
(Fig. 1, Panel A, Lane 2) and immunoblots (Fig. 1, Panel A,
Lane 4). Bands at 65 and 45 kDa were visible in the SDS-
PAGE gel, while only the 45-kDa protein was identified in the
immunoblot using an anti-his-tag antibody. Thus, the 65-kDa
protein seen in the SDS-PAGE gel may have been a
contaminant protein.
His-tagged transglutaminases were expressed in SF21 insect
cells, purified using nickel columns and analyzed in SDS-
PAGE gels and immunoblots (Fig. 1, Panel B). For transglu-
taminase 1, bands at approximately 100 kDa and 65 kDa were
visible in the SDS-PAGE gel (Fig. 1, Panel B, Lane 1), while
only the 100-kDa protein was identified in the immunoblot
using an anti-his-tag antibody (Fig. 1, Panel B, Lane 3). Thus,Fig. 1. Analysis of recombinant proteins used in the in vitro cross-linking assay.
immunoblot analysis, respectively, of his-tagged E1^E4 protein. Lanes 2 and 4: SDS
analysis of his-tagged transglutaminases. Lanes 1 and 3: SDS-PAGE and immunobl
PAGE and immunoblot analysis, respectively, of his-tagged transglutaminase 3. Pa
dispase-digested transglutaminase 3. Antibody used for all immunoblots was a rabb
(in kDa) are indicated on the left side of each panel.as above, the 65-kDa protein seen in the SDS-PAGE gel may
have been a contaminant protein.
His-tagged transglutaminase 3 proenzyme (i.e., the trans-
glutaminase 3 protein prior to activation by digestion with
dispase) appeared in the gel (Fig. 1, Panel B, Lane 2) and
immunoblot (Fig. 1, Panel B, Lane 4) as a single band of
approximately 90 kDa. Following digestion of transglutami-
nase 3 with dispase, a second immunoblot was performed that
demonstrated the 90-kDa his-tagged transglutaminase 3 pro-
enzyme prior to proteolytic cleavage (Fig. 1, Panel C, Lane 1),
then as a 60-kDa activated, his-tagged transglutaminase 3
enzyme band after dispase digestion (Fig. 1, Panel C, Lane 2).
The C-terminal 30 kDa fragment of the transglutaminase
proenzyme did not appear on the immunoblot, most likely
because the hexa-histidine tag was fused at the N-terminus of
the protein.
E1^ E4 cross-linking by endogenous transglutaminases in
tissue sections
Sections of neonatal foreskin tissue were analyzed for tissue
histology (Fig. 2, Panel A) and for the presence of transglu-
taminase 3 in immunohistochemical assays using a mouse
monoclonal antibody (Fig. 2, Panel B). Transglutaminase 3
was detected in the suprabasal layers of epithelium. To our
knowledge, a monoclonal antibody against transglutaminase 1
is not available; therefore we could not test specifically for the
location of transglutaminase 1 in the foreskin epithelium.
We next performed an experiment using an in situ assay to
provide evidence for incorporation of E1^E4 protein into the
cell envelope by endogenous transglutaminases in neonatal
foreskin tissue. Photomicrographs of Panels C through F were
taken at the same exposure time, and a high degree of
fluorescence was present only in the assay in which his-tagged
E1^E4 protein and calcium were present (Fig. 2, Panel C). The
highest degree of fluorescence was present in the most
differentiated keratinocytes, in the region of the cornified cell
envelope. No significant fluorescence was noted in the assay in
which EDTAwas added and calcium omitted (Fig. 2, Panel D).
The higher abundance of E1^E4 in the more differentiatedPanel A: analysis of recombinant proteins. Lanes 1 and 3: SDS-PAGE and
-PAGE and immunoblot analysis, respectively, of his-tagged loricrin. Panel B:
ot analysis, respectively, of his-tagged transglutaminase 1. Lanes 2 and 4: SDS-
nel C: Lane 1: immunoblot analysis of his-tagged transglutaminase 3. Lane 2:
it polyclonal antibody against the hexa-histidine tag. Molecular weight markers
Fig. 3. In vitro cross-linking assays. Antibody used for all immunoblots in the
cross-linking assay was a rabbit polyclonal antibody against the hexa-histidine
tag. Panel A: in vitro cross-linking assay using his-tagged loricrin as a
substrate. Lane 1: loricrin cross-linking assay in substrate buffer (Tris–HCl 10
mM, pH 8.4, calcium chloride 5 mM) with no added transglutaminase 3. Lane
2: loricrin cross-linking assay in substrate buffer with transglutaminase 3 added
Large arrows indicate ‘‘fast migrating dimer’’; small arrow indicates the ‘‘fas
migrating monomer’’. Panel B: in vitro cross-linking assay using his-tagged
E1^E4 as a substrate. Lane 1: his-tagged E1^E4 protein in Tris–HCl 10 mM
pH 8.4, shown as an indicator for the amount of E1^E4 added to cross-linking
reactions. Lane 1 does not depict a cross-linking reaction. Lane 2: cross-linking
assay of his-tagged E1^E4 protein in substrate buffer (Tris–HCl 10 mM, pH
8.4, calcium chloride 5 mM) with added transglutaminase 3. Lane 3: E1^E4
protein in Tris–HCl 10 mM, pH 8.4 with transglutaminase 3 added, but no
added calcium chloride in the reaction. Lane 4: cross-linking assay of his
tagged E1^E4 protein in control buffer (Tris–HCl, 10 mM, pH 8.4, EDTA 1
mM) with transglutaminase 3 added. Large arrow indicates the position of the
loading wells and the small arrow indicates the E1^E4 monomer. Panel C
E1^E4 protein, in amounts equal to the in vitro cross-linking reaction shown in
Panel B, were incubated overnight at 37 -C without the addition o
transglutaminase 3, in either distilled water (Lane 1) or Tris–HCl 10 mM
pH 8.4 (Lane 2). Large arrow indicates the position of the loading wells and the
small arrow indicates the E1^E4 monomer. Molecular weight markers (in kDa
are indicated on the left side of the figure.
Fig. 2. Analysis of foreskin epithelium and the in situ cross-linking assay. Panel
A: histologic analysis of foreskin epithelium, stained with hematoxylin and
eosin. Panel B: immunohistochemical analysis of epithelium using a mouse
monoclonal antibody to detect transglutaminase 3. Panel C: in situ cross-linking
assay. HPV 11 E1^E4 protein and substrate buffer (Tris–HCl 100 mM, pH 8.4,
calcium chloride 5 mM) added. Panel D: in situ cross-linking assay. E1^E4
protein and control buffer (Tris–HCl 100 mM, pH 8.4, EDTA 5 mM) added.
Panel E: in situ cross-linking assay. Substrate buffer with no added E1^E4
protein. Panel F: in situ cross-linking assay. E1^E4 protein and substrate buffer,
but no primary antibody against the hexa-histidine tag added. Arrows in each
panel indicate the basal layer of epithelium. All photomicrographs were taken
at the same time exposure. Original magnification: 200.
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was added (Fig. 2, Panel C), suggested that non-specific
binding of E1^E4 to keratins had not occurred, since keratins
are abundant in all keratinocytes, including those in the basal
layer of epithelium.
No fluorescence was noted in the assay in which E1^E4 was
omitted (Fig. 2, Panel E). Similarly, no significant fluorescence
was observed in the assay in which anti-hexa-histidine
antibodies were omitted (Fig. 2, Panel F).
E1^ E4 is cross-linked in vitro by recombinant
transglutaminase 3
We next performed in vitro cross-linking experiments using
recombinant transglutaminases 1 and 3. Recombinant his-
tagged loricrin was used as a substrate in control assays fortransglutaminase-mediated cross-linking (Fig. 3, Panel A).
Loricrin appeared as a 45-kDa monomer in immunoblots of
cross-linking assays in which transglutaminase (in this case,
transglutaminase 3) was omitted (Fig. 3, Panel A, Lane 1), and
as ‘‘fast loricrin monomers’’ of approximately 35 kDa and ‘‘fast
loricrin dimers’’ of approximately 60 kDa in assays containing
transglutaminase (Fig. 3, Panel A, Lane 2). The rapid migration
of cross-linked loricrin, a glycine- and serine-rich protein, has
been described previously by Candi et al., and is thought to be
caused by intramolecular cross-linking (Candi et al., 1995,
2001). In assays using recombinant transglutaminase 1, similar
results to the transglutaminase 3 experiments were found using
loricrin as a substrate (data not shown).
Recombinant his-tagged HPV 11 E1^E4 protein was used in
cross-linking experiments with recombinant transglutaminase 1
or transglutaminase 3. No evidence of cross-linking was found
with transglutaminase 1 (data not shown). In contrast, reactions
in which transglutaminase 3 was present produced the
appearance of high molecular weight, immunoreactive com-
plexes and a marked reduction in monomeric E1^E4 protein
indicated that cross-linking between molecules had occurred
(Fig. 4, Panel B, Lanes 1 and 2). Cross-linking assays of E1^E4








Fig. 4. Immunofluorescence microscopic analysis of expression of GFP (Panel A), GFP-E1^E4 (Panel B), or non-fused E1^E4 protein (Panel C) in undifferentiated
NIKS cells transduced with recombinant retroviruses and grown in selective medium. All photomicrographs were taken at the same time exposure. Original
magnification 400.
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High molecular weight multimers were present, although
monomeric E1^E4 was present in greater abundance than in
the assay containing added calcium. Aggregates of approxi-
mately 30, 45, and 60 kDa were present in this reaction, which
may have resulted from E1^E4 self-aggregation. In the reaction
containing EDTA, a further reduction of cross-linking oc-
curred, as evidenced by the increased presence of E1^E4
monomeric protein (Fig. 3, Panel B, Lane 4). Aggregates of 30,
45, and 60 kDa were also present in this reaction.
Because E1^E4 can self-aggregate (Ashmole et al., 1998;
Bryan et al., 1998; Roberts et al., 1994), E1^E4 protein, in
amounts equal to the in vitro cross-linking reaction, were
incubated overnight at 37 -C without the addition of
transglutaminase, in either distilled water (Fig. 3, Panel C,
Lane 1) or Tris–HCl 10 mM, pH 8.4 (Fig. 3, Panel C, Lane 2).
We found no reduction in the abundance of E1^E4 monomer in
these reactions. However, aggregates of approximately 30, 45,
and 60 kDa were formed, similar to the reaction containing
transglutaminase 3 and EDTA (Fig. 3, Panel B, Lane 4). Thus,
the complexes at 30, 45, and 60 kDa were likely due to self-
aggregation of E1^E4 protein rather than by cross-linking
mediated by transglutaminase 3.
E1^ E4 alters morphology of differentiated keratinocytes and
cell envelopes
If E1^E4 is cross-linked by keratinocyte transglutaminases,
then the morphologic properties of cells transduced by retro-
viruses expressing E1^E4, and cornified cell envelopes from
these cells may differ from control cells. We thereforeFig. 5. NIKS cells transduced with recombinant retroviruses and induced to differe
expressing GFP. Panel B: cells transduced with retroviruses expressing GFP-E1^
Original magnification 200.expressed E1^E4 in NIKS cells, induced the cells to
differentiate by growth in medium containing 2 mM calcium
chloride, isolated cell envelopes, and examined them for
morphologic features.
Undifferentiated NIKS cells transduced with retroviruses
expressing GFP and selected with G418 demonstrated diffuse
green fluorescence in nearly all cells (Fig. 4, Panel A). Cells
transduced with retroviruses expressing GFP-E1^E4 demon-
strated fluorescence in an intermediate filament distribution in
nearly all cells (Fig. 4, Panel B). Cells transduced with
retroviruses expressing non-fused E1^E4 were probed with
an antibody raised against the E1^E4 protein. These cells
demonstrated fluorescence in an intermediate filament distri-
bution in nearly all cells, similar to, but less intense than that
seen for GFP-E1^E4 expression (Fig. 4, Panel C).
Differentiated NIKS cells expressing GFP, GFP-E1^E4, or
E1^E4 were prepared by grown in medium containing 2 mM
calcium chloride as described in Methods. Cells were harvested
using a cell scraper, and a portion was fixed in zinc formalin,
embedded in paraffin, and sections were prepared. One section
from each preparation was stained with hematoxylin and eosin.
Differentiated cells expressing GFP demonstrated appeared
organized and uniform in size and shape (Fig. 5, Panel A). The
nuclei of these cells were also uniform in size and shape. In
contrast, differentiated cells expressing GFP-E1^E4 or non-
fused E1^E4 were varied in size and shape (Fig. 5, Panels B
and C). The nuclei of these cells were also varied in size and
shape.
Next, cornified cell envelopes were prepared from differ-
entiated NIKS cells by heating to 80 -C in 1% SDS for 4 h,
concentration by centrifugation, and analysis by phase contrastntiate. Light microscopic analysis. Panel A: cells transduced with retroviruses
E4. Panel C: cells transduced with retroviruses expressing non-fused E1^E4.
Fig. 6. Cell envelopes from NIKS cells transduced with recombinant retroviruses and induced to differentiate. Phase contrast analysis. Panel A: cell envelopes from
cells transduced with retroviruses expressing GFP. Panel B: cell envelopes from cells transduced with retroviruses expressing GFP-E1^E4. Panel C: cell envelopes
from cells transduced with retroviruses expressing non-fused E1^E4. Original magnification 400.
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cells expressing GFP were consistently round or cuboidal (Fig.
6, Panel A). In contrast, cell envelopes from cells expressing
GFP-E1^E4 or non-fused E1^E4 were small and rough
bordered, and appeared fragmented in many cases (Fig. 6,
Panels B and C).
Discussion
The mechanisms that facilitate release of newly formed
HPV from the differentiated keratinocyte are not completely
understood. HPV infection is not a lytic process, and therefore
some other method must exist for newly formed virions to
escape the infected cell. We previously showed that HPV
infection weakens the cornified cell envelope, and that the
composition of the cell envelope matrix is altered in HPV 11
infection; most notably with a reduction in loricrin and an
increase in the small proline-rich proteins (Brown and Bryan,
2000; Lehr et al., 2002).
Could E1^E4 have a role in release of mature HPV particles
from the differentiated keratinocyte? The E1^E4 protein and
the L1 major capsid protein are expressed from a bicistronic
transcript (Brown et al., 1996; Chow et al., 1987; Nasseri et al.,
1987). Interestingly, nearly all cells in natural lesions such as
condylomata acuminata and low grade dysplastic lesions of the
cervix containing detectable amounts of the L1 major capsid
protein also contain detectable E1^E4 protein (Brown et al.,
1994; Doorbar et al., 1997). In addition, the HPV 11 E1^E4
protein localizes to the region of the cell envelope, co-purifies
with cell envelopes from these tissues, and is associated in vivo
with the cell envelope structure in immunoelectron microscopic
studies (Bryan and Brown, 2000).
We show here that the HPV 11 E1^E4 protein can serve as a
substrate for keratinocyte transglutaminases, the enzymes that
cross-link precursor proteins including loricrin, involucrin,
small proline rich proteins (SPRs), and cytokeratins to form the
dense, insoluble cornified cell envelope (Aeschlimann and
Paulsson, 1994; Candi et al., 1999; Friedrich et al., 1999; Kim
et al., 1995; Steinert and Marekov, 1999; Steven and Steinert,
1994). Transglutaminases are expressed in differentiated
epithelium and are dependent on the presence of calcium for
optimal activity. Transglutaminases-mediated cross-linking
results in the formation of large macromolecules, formed by
inter- and intramolecular isopeptide bonding between gluta-
mine and lysine residues (Kalinin et al., 2002; Nemes and
Steinert, 1999; Steinert and Marekov, 1999). Transglutaminase1 is membrane bound and is involved in early cross-linking
events such as cross-linking of involucrin, a cell envelope
‘‘scaffold’’ protein. Transglutaminase 3 is soluble in the
cytoplasm and is involved in later cross-linking events, such
as cross-linking of loricrin.
Transglutaminase substrates contain lysine or glutamine
residues and are cytoplasmic in location. The HPV 11 E1^E4
protein is 90 amino acids in length, containing three lysine and
three glutamine residues. E1^E4 proteins are detected in the
cytoplasm of infected keratinocytes, and become increasingly
abundant as the keratinocyte differentiates (Brown et al., 1994,
2004; Doorbar et al., 1986, 1997). Lysine and glutamine
residues are present in E1^E4 proteins of HPV types 6, 11, 16,
18, 59, and 83. HPV 16 E1^E4 contains six lysine and five
glutamine residues. Several of these lysine and glutamine
residues are highly conserved in E1^E4 proteins of different
HPV types. Thus, E1^E4 proteins appears to meet the basic
requirements of a potential transglutaminase substrate.
We also show here that expression of E1^E4 protein in
differentiated human keratinocytes is associated with morpho-
logic changes in the cells themselves, and in the cell envelopes
that are derived from these cells. These morphologic differ-
ences were similar to those between healthy and HPV-infected
genital epithelium, suggesting that E1^E4 expression in
differentiated human keratinocytes may have had a specific
effect on development of the cornified cell envelope. However,
our studies do not yet provide definitive proof that E1^E4
protein is incorporated into the cornified cell envelope in
natural infection. Further work needs to be done to prove that
an isopeptide bond is formed with loricrin, an SPR, or other
cell envelope protein, and which E1^E4 residues are involved.
This definitive proof will require isolation, purification, and
sequencing of small, cross-linked peptides isolated from
trypsin-digested cross-linking reaction products, or purified
cornified cell envelopes from infected tissues (Steinert and
Marekov, 1997; Steinert et al., 1998). We have begun studies
using these methodologies.
Our studies do not prove that E1^E4 protein causes the
abnormalities of cell envelopes seen in HPV infection. Such a
cytopathic effect is likely to be multifactorial. In addition, it is
likely that E1^E4 has numerous functions, based on prior
studies of E1^E4 function (Davy et al., 2002; Doorbar et al.,
1991, 2000; Nakahara et al., 2002; Roberts et al., 1994; Wang
et al., 2004). The HPV 11 E1^E4, a protein expressed in
differentiated cells of infected epithelium, appears to be a
satisfactory substrate for transglutaminase 3, the enzyme
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cornified cell envelope components into the cornified cell
envelope during the process of keratinocyte differentiation.
This finding may explain the co-localization of the HPV 11
E1^E4 protein with the cell envelope in natural infection, and
the co-purification of E1^E4 with cornified cell envelope
fragments. As with all observations with E1^E4 proteins,
further work is needed to determine the functional significance
of our findings in natural HPV infection.
Methods
Cloning and expression of HPV 11 E1^ E4, loricrin, and
transglutaminases
The HPV 11 E1^E4 sequence was previously cloned by RT-
PCR using RNA purified from an HPV 11-infected human
xenograft grown in an athymic mouse (Brown et al., 1994).
The E1^E4 sequence was subcloned from pCR3.1 into
pET28A (Novagen, Madison, WI). For expression of E1^E4
protein, competent BL21 (DE3) pLysS E. coli (Invitrogen,
Carlsbad, CA) were transformed with the pET28A-E1^E4 11
according to manufacturer’s instructions. A single transformed
colony was used to inoculate LB growth medium containing
ampicillin (50 Ag/mL). The culture was grown in a shaking
incubator at 37 -C to an optical density of 0.6 at 540 nm, at
which time IPTG was added to a final concentration of 0.4
mM. The cells were grown for an additional 3 h in a shaking
incubator at 37 -C. Cells were then harvested by centrifugation
and expression verified by immunoblots using a rabbit
polyclonal antibody directed against the hexa-histidine tag or
antibodies specifically directed against the HPV 11 E1^E4
protein (Brown et al., 1994). E1^E4 protein was then purified
from the cell extract under denaturing conditions using a nickel
resin column (Ni-NTA His Bind) according to manufacturer’s
instructions (Novagen), and dialyzed against 1 PBS.
For loricrin cloning, a cDNA library was prepared from
human neonatal foreskin tissue using the Smart PCR cDNA
Synthesis Kit as directed by the manufacturer (Clontech, Palo
Alto, CA). The loricrin gene was then amplified by from this
library by PCR using the primers: 5V CAA GAT GTC TTC
TCA GAA AAA GCA GCC CAC and 3VCTATTT GGA CGG
CCA GGT AGG CGC. Conditions used for the PCR were: 94
-C hold for 5 min, followed by 35 cycles of 94 -C for 1 min, 68
-C for two and one half minute, followed by a 5-min hold at 72
-C. The loricrin amplimer of approximately 1100 bp was
purified from a gel fragment and cloned into the pCR3.1 vector
(Invitrogen, Carlsbad, CA). The loricrin sequence was then
subcloned into pET28A. The loricrin sequence and the in-
frame 5V hexa-histidine sequences were then subcloned from
the pET28A vector into the pBacPAK9 vector (BD Bios-
ciences, Palo Alto, CA). DNA sequencing was then performed
on all clones in both directions to confirm correct amplification
and cloning of the loricrin open reading frame.
The transglutaminase 1 ORF was amplified by RT-PCR from
the foreskin cDNA library using the primers: 5VGTCGACGTC-
CTTGCTCATCTGACTCC and 3V GTACTGCGGTTGCCAA-CACT. The Expand Long Template PCR system (Roche
Molecular Diagnostics, Carmel, IN) was used (with Buffer 1)
to amplify transglutaminase 1 using the conditions: 94 -C hold
for 2min, followed by ten cycles of 94 -C for 20 s, 56 -C for 30 s,
and 68 -C for 3 min, followed by three more rounds of ten cycles
each, with an extra minute of extension at 68 -C for each of the
three additional rounds.
The transglutaminase 1 amplimer of approximately 2200 bp
was purified from a gel fragment and cloned into the pXL-Topo
II vector (Invitrogen). The transglutaminase 1 sequence was
then subcloned into pET28A. The transglutaminase 1 sequence
and the in-frame 5V hexa-histidine sequence were then
subcloned into the pBacPAK9 vector (BD Biosciences, Palo
Alto, CA). DNA sequencing was performed in both directions
to confirm proper cloning of the transglutaminase 1 open
reading frame.
The transglutaminase 3 ORF was amplified by RT-PCR
from the foreskin cDNA library using the primers: 5V
TGGATCCGGATCCAACATGGCTGCTCTAGGAGT and 3V
TGCGGCCGCGTCGACTGCTCCGTGTTGTCCAAGTT.
The Expand Long Template PCR system (Roche Molecular
Diagnostics) was used (with Buffer 1) to amplify transgluta-
minase 3 using the same conditions as above for transgluta-
minase 1. The transglutaminase 3 amplimer of approximately
2000 bp was purified from a gel fragment and cloned into the
pXL-Topo II vector (Invitrogen). The transglutaminase 3
sequence were then subcloned into pET28A. The transgluta-
minase 3 sequence and the in-frame 5V hexa-histidine sequence
was then subcloned from the pET28A vector into pBacPAK8
vector (BD Biosciences). DNA sequencing was performed in
both directions to confirm proper cloning of the transglutami-
nase 3 open reading frame.
Competent Sf21 insect cells (Clontech) were transformed
with the pBacPAK9-loricrin, pBacPAK9-transglutaminase 1, or
pBacPAK8-transglutaminase 3 plasmids as directed by the
manufacturer. Cells were grown for 4 days at 27 -C and then
harvested using PopCulture (with added Benzonase reagent at
0.4 AL/mL of original culture volume) according to the
manufacturer’s instructions (Novagen). Protease inhibitor
cocktail III (Calbiochem, San Diego, CA) was added at 0.1
AL/mL (original culture volume) to the lysates. Cells were then
harvested by centrifugation and proteins purified in non-
denaturing conditions using a nickel resin column as above
according to manufacturer’s instructions (Novagen), then
dialyzed against 1 PBS. Immunoblots were performed using
a rabbit polyclonal antibody against the hexa-histidine tag to
verify expression of E1^E4, loricrin, transglutaminase 1, and
transglutaminase 3.
In situ cross-linking assay
The in situ cross-linking assay utilized frozen sections of
human foreskin tissue derived from neonatal circumcisions.
This assay has provided evidence of incorporation of numerous
cellular proteins into genital epithelium, and presumably into
the cornified cell envelope by the activity of transglutaminases
(Akiyama et al., 2000; Raghunath et al., 1998). A portion of the
D.R. Brown et al. / Virology 345 (2006) 290–298296tissue was embedded in paraffin, and sections were prepared
for histologic and immunohistochemical analysis as previously
described, using a mouse monoclonal antibody against human
transglutaminase 3 (Hitomi et al., 2003a, 2003b).
For the cross-linking assay, cryostat sections (6 Am thick)
were air dried for 10 min at room temperature, then incubated
for 60 min at room temperature in blocking buffer (Tris–HCl
100 mM, pH 8.4, BSA 1%). The sections were washed three
times in 1 phosphate-buffered saline (PBS), pH 8.4. The
sections were incubated with substrate buffer (Tris–HCl 100
mM, pH 8.4, calcium chloride 5 mM) for 5 h at room
temperature. The sections were then washed three times in 1
PBS. His-tagged HPV 11 E1^E4 protein was added to substrate
buffer at an approximate concentration of 70 ng/AL, and 100
AL of substrate buffer with added E1^E4 protein was applied
the tissue section. Following an overnight incubation at room
temperature, the sections were incubated in stop buffer (1
PBS, EDTA 25 mM) for 10 min at room temperature.
The sections were again washed three times with 1 PBS,
and a primary rabbit polyclonal serum against the hexa-
histidine tag (Santa Cruz Biotechnology, Inc., Santa Cruz,
CA) was added (1:100 in 1 PBS) for 2 h at room temperature,
followed by three additional washes with 1 PBS. A secondary
swine anti-rabbit FITC-conjugated antibody (Dako Cytomation
California Inc., Carpinteria, CA) was applied (1:100 dilution in
1 PBS) and the sections were incubated for 2 h at room
temperature, followed by washing three times with 1 PBS.
The sections were then mounted with Vectashield (Vector
Laboratories, Burlingame, CA) and viewed under the fluores-
cent microscope at 488 nm wavelength. Photomicrographs
were taken of all sections at the same exposure time.
Because transglutaminases are dependent on calcium for
activity, an experiment was performed using a control buffer
(Tris–HCl 100 mM, pH 8.4, EDTA 5 mM) in place of the
substrate buffer, which contained calcium chloride. To deter-
mine if the serum against the hexa-histidine tag bound non-
specifically to the tissue section, an additional control experi-
ment was performed that included substrate buffer, but E1^E4
protein was omitted. Lastly, an experiment was performed that
utilized E1^E4 protein in substrate buffer, omission of the
serum against the hexa-histidine tag, followed by incubation in
the FITC-conjugated secondary antibodies as indicated above.
In vitro cross-linking assay
The in vitro cross-linking assay was performed using non-
denatured transglutaminase 1 or transglutaminase 3 to deter-
mine if HPV 11 E1^E4 protein could serve as a substrate for
these enzymes. Loricrin was used as a control substrate for
transglutaminase 1 or transglutaminase 3 cross-linking. This in
vitro cross-linking assay has been used to provide evidence of
incorporation of numerous cellular proteins into the cornified
cell envelope by the activity of transglutaminases (Candi et al.,
1995, 2001). The proenzyme of transglutaminase 3 (but not
transglutaminase 1) requires activation by proteolytic cleavage
before it effectively cross-links precursor molecules (Hitomi et
al., 2003a, 2003b). Transglutaminase 3 was activated by addingneutral dispase I (Roche Applied Science, Indianapolis, IN) to
a concentration of 0.0015 units/AL and incubating 37 -C for 30
min. Immunoblots were then performed to demonstrate
cleavage of transglutaminase 3 into active peptide fragments
of the appropriate size.
Transglutaminase 1 (or activated transglutaminase 3) and
loricrin (or HPV 11 E1^E4) were added to a substrate buffer
(Tris–HCl 10 mM, pH 8.4, calcium chloride 5 mM). Reactions
were also performed using substrate buffer with no added
calcium chloride, and using substrate buffer with EDTA 5 mM
and no added calcium chloride.
To provide further evidence that transglutaminase-mediated
cross-linking was responsible for any observed reduced
abundance of monomeric E1^E4 protein or the formation of
high molecular weight complexes, E1^E4 protein in an amount
equal to that in cross-linking reactions was incubated at 37 -C
overnight in water or in Tris–HCl, 10 mM, pH 8.4.
Equal volumes of all reactions were separated by SDS-
PAGE electrophoresis followed by transfer to nitrocellulose
membrane Bio-Rad Laboratories, Hercules, CA) as previously
described (Brown et al., 1994). Membranes were probed with
polyclonal serum against the hexa-histidine tag to determine if
a reduction in the abundance of monomeric loricrin or E1^E4
occurred, if a mobility shift could be detected, or if high
molecular weight complexes formed.
Retroviruses and expression of E1^ E4 in NIKS cells
The GFP sequence, the GFP-E1^E4 sequence, or E1^E4
sequences (Bryan et al., 1998) were cloned into the pLNCX2
vector (Clontech, Palo Alto, CA). Plasmids were sequenced in
both directions. Construction of vector packaging cell lines was
performed at the Indiana University School of Medicine Vector
Laboratory using established methods (Kotani et al., 1994;
Markowitz et al., 1988). Briefly, each plasmid construct was
transfected into the PG13 cell line (Miller et al., 1991).
Supernatant containing the transiently expressed, GALV
pseudotyped vector was collected at 24 h post-transfection
media change. The harvested vector containing supernatant
was then used to transduce the phoenix ampho packaging cell
line (http://www.stanford.edu/group/nolan/MTAs/mtas.html).
Transduction of the phoenix ampho cell line was carried out
by doing three rounds of spinoculation (Kotani et al., 1994).
The transduced phoenix ampho cell population (producer cells)
was used to produce the retroviral vector used in the rest of the
experiments reported here.
Supernatants (containing retroviruses) from producer cells
were frozen in growth medium (DMEM plus 10% calf serum).
NIKS cells were grown to 60% confluence in Complete F
medium in the presence of mitomycin C-treated J2 cells as
previously described (Brown et al., 2004). Supernatants were
thawed on ice, and 2 mL was added to 3 mL of complete F
medium, then mixed well by inversion and added to NIKS
cells. Polybrene (Sigma Aldrich Chemicals, St. Louis, MO)
was added to the medium at a final concentration of 8 Ag/mL.
Transduction was thus performed for 4 h at 37 -C in 5% CO2.
The medium containing retroviruses was replaced after 4 h with
D.R. Brown et al. / Virology 345 (2006) 290–298 297fresh Complete F medium. The transduction procedure was
repeated for 4 h the next day. NIKS cells were split and re-
plated onto mitomycin-treated J2 cells after 96 h. A drop of
cells was grown on a glass cover slip each time NIKS cells
were split for analysis of expression.
Transduced NIKS cells were then grown to confluence in
Complete F medium containing G418 200 Ag per mL, at which
time 2 mM calcium chloride was added to induce differenti-
ation. Medium was changed every 48 h. Cells were grown for
21 additional days, then harvested with a cell scraper. A portion
of the cells was fixed with zinc formalin for preparation of
paraffin-embedded sections. Some of the cells were used to
prepare cornified cell envelopes as previously described
(Brown and Bryan, 2000).
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